3 Biotech Stocks to Buy on the Dip: August 2024

06:00am, Thursday, 15'th Aug 2024
With the current market volatility, knowing which biotech stocks to buy on the dip can lead to lucrative returns as the industry is likely to recover faster than the market average. After all, many of
Eli Lilly may be starting to gain an edge over Novo Nordisk in the GLP-1 market. Meanwhile, Stryker will acquire artificial intelligence startup Care.ai.
Glp-1 drugs are predicted to become the top-selling pharmaceutical class ever, with projected US sales of $150 billion by 2030. I have written multiple articles on Glp-1 drugs, highlighting their pote
Eli Lilly has sent cease-and-desist letters to US healthcare providers in recent days demanding they stop promoting copycat weight-loss drugs as the supply of the company's drug Zepbound improves, Blo
Eli Lilly (LLY) is a great stock to have in one's portfolio currently based on its strong overall financial performance and robust drug pipeline.
The market reacted very positively to Eli Lilly's Q2 earnings report. This isn't the first time the stock has seen a significant run-up in a short period.
Treating aging and its consequences will be a colossal market. The first seeds of the coming boom have already been planted.

Lilly (LLY) Upgraded to Buy: Here's Why

01:00pm, Tuesday, 13'th Aug 2024
Lilly (LLY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here we discuss three drugmakers, Eli Lilly and Company (LLY), Pfizer (PFE) and AbbVie (ABBV), following their increase in sales and earnings guidance for 2024.
For U.S. stocks, quarterly earnings seasons are set up to follow an old “beat-and-raise” pattern, which can lift share prices. A look ahead at earnings estimates for 2025 highlights a group of com
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
A large majority of the companies have already reported second-quarter results. While we can call it a mixed earnings season, there are a few companies that beat expectations and reported record reven
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Eli Lilly stock (NYSE: LLY) recently reported its Q2 results, with revenues and earnings exceeding the street expectations. The pharmaceutical giant reported sales of $11.3 billion and adjusted earnin
Lilly Seaport Innovation Center (LSC) serves as the central hub for Lilly's genetic medicines efforts and houses the first East Coast Lilly Gateway Labs New 346,000 square foot facility will accommoda
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE